Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


1 Eur J Gastroenterol Hepatol
1 Haemophilia
1 J Gastroenterol
4 J Hepatol
1 J Med Virol
1 Lancet Gastroenterol Hepatol
3 PLoS One
1 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Eur J Gastroenterol Hepatol

  1. EL-MAKSOUD MA, Habeeb MR, Ghazy HF, Nomir MM, et al
    Clinicopathological study of occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma.
    Eur J Gastroenterol Hepatol. 2019 Mar 11. doi: 10.1097/MEG.0000000000001388.
    PubMed     Text format     Abstract available


  2. CARMO RA, Martins ML, Chaves DG, Dezanet LNC, et al
    Prevalence and risk factors associated with hepatitis C among Brazilian male patients with haemophilia: A long-term follow-up.
    Haemophilia. 2019 Mar 13. doi: 10.1111/hae.13728.
    PubMed     Text format     Abstract available

    J Gastroenterol

  3. NAGANUMA A, Chayama K, Notsumata K, Gane E, et al
    Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
    J Gastroenterol. 2019 Mar 13. pii: 10.1007/s00535-019-01569.
    PubMed     Text format     Abstract available

    J Hepatol

  4. TOYODA H, Kumada T, Tada T, Mizuno K, et al
    Imaging basis of AFP and WFA(+)M2BP as indicators of the risk of HCC after SVR.
    J Hepatol. 2018;68:606-607.
    PubMed     Text format    

  5. WYLES D, Weiland O, Yao B, Weilert F, et al
    Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.
    J Hepatol. 2019 Mar 8. pii: S0168-8278(19)30078.
    PubMed     Text format    

  6. NAKAO Y, Hashimoto S, Abiru S, Komori A, et al
    Rapidly growing, moderately differentiated HCC: A clinicopathological characteristic of HCC occurrence after IFN-free DAA therapy?
    J Hepatol. 2018;68:854-855.
    PubMed     Text format    

  7. CAMMA C, Leandro G
    Direct antiviral agents and risk of HCC: Waiting for Godot.
    J Hepatol. 2018;68:614-616.
    PubMed     Text format    

    J Med Virol

  8. HUANG R, Rao H, Xie Q, Gao Z, et al
    Comparison of Efficacy of Sofosbuvir plus Ribavirin in Chinese Patients with Genotype 3a or 3b HCV Infection.
    J Med Virol. 2019 Mar 12. doi: 10.1002/jmv.25454.
    PubMed     Text format     Abstract available

    Lancet Gastroenterol Hepatol

  9. NGUYEN-KHAC E, Thiele M, Voican C, Nahon P, et al
    Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis.
    Lancet Gastroenterol Hepatol. 2018;3:614-625.
    PubMed     Text format     Abstract available

    PLoS One

  10. JONES EA, Linas BP, Truong V, Burgess JF, et al
    Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
    PLoS One. 2019;14:e0213745.
    PubMed     Text format     Abstract available

  11. LE NGOC C, Tran Thi Thanh T, Tran Thi Lan P, Nguyen Mai T, et al
    Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam.
    PLoS One. 2019;14:e0212734.
    PubMed     Text format     Abstract available

  12. TAKAHASHI A, Moriya K, Ohira H, Arinaga-Hino T, et al
    Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey.
    PLoS One. 2018;13:e0204772.
    PubMed     Text format     Abstract available

    Proc Natl Acad Sci U S A

  13. FURUSE Y
    Analysis of research intensity on infectious disease by disease burden reveals which infectious diseases are neglected by researchers.
    Proc Natl Acad Sci U S A. 2018 Dec 31. pii: 1814484116.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.